Beroni Group Limited

OTCQB:BNIGF USA Drug Manufacturers - Specialty & Generic
Market Cap
$284.04K
Market Cap Rank
#42004 Global
#13629 in USA
Share Price
$0.01
Change (1 day)
+0.00%
52-Week Range
$0.01 - $0.01
All Time High
$218.00
About

Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics, and viral diagnostic kits in China. It operates through four segments: Cell Therapies; Developing New Anti-Cancer Drugs; E-commerce Platform for Pharmaceutical and Healthcare Products; and Det… Read more

Beroni Group Limited (BNIGF) - Net Assets

Latest net assets as of June 2024: $5.56 Million USD

Based on the latest financial reports, Beroni Group Limited (BNIGF) has net assets worth $5.56 Million USD as of June 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.44 Million) and total liabilities ($2.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $5.56 Million
% of Total Assets 65.87%
Annual Growth Rate N/A
5-Year Change -100.0%
10-Year Change N/A
Growth Volatility 144.01

Beroni Group Limited - Net Assets Trend (2015–2023)

This chart illustrates how Beroni Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Beroni Group Limited (2015–2023)

The table below shows the annual net assets of Beroni Group Limited from 2015 to 2023.

Year Net Assets Change
2023-12-31 $-214.00 -100.00%
2022-12-31 $7.58 Million -8.72%
2021-12-31 $8.31 Million -17.42%
2020-12-31 $10.06 Million -23.36%
2019-12-31 $13.13 Million -28.05%
2018-12-31 $18.24 Million +68.69%
2017-12-31 $10.82 Million +401.97%
2016-12-31 $2.15 Million +28.10%
2015-12-31 $1.68 Million --

Equity Component Analysis

This analysis shows how different components contribute to Beroni Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4196511900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2023)

Component Amount Percentage
Other Components $42.10 Million %
Total Equity $-161.20K 100.00%

Beroni Group Limited Competitors by Market Cap

The table below lists competitors of Beroni Group Limited ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Beroni Group Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from 7,261,042 to -161,197, a change of -7,422,239 (-102.2%).
  • Net loss of 9,227,128 reduced equity.
  • Other factors increased equity by 1,804,889.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income $-9.23 Million -5724.13%
Other Changes $1.80 Million +1119.68%
Total Change $- -102.22%

Book Value vs Market Value Analysis

This analysis compares Beroni Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 $0.00 $0.01 x
2016-12-31 $0.00 $0.01 x
2017-12-31 $0.15 $0.01 x
2018-12-31 $0.25 $0.01 x
2019-12-31 $0.18 $0.01 x
2020-12-31 $0.12 $0.01 x
2021-12-31 $0.10 $0.01 x
2022-12-31 $0.09 $0.01 x
2023-12-31 $-0.01 $0.01 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Beroni Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1968.54%
  • • Asset Turnover: 0.05x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-35.26%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -9.46% -14.41% 0.45x 1.45x $-327.35K
2016 22.09% 10.91% 0.96x 2.11x $260.42K
2017 -6.70% -31.65% 0.20x 1.04x $-1.81 Million
2018 -13.28% -112.21% 0.12x 1.02x $-4.26 Million
2019 -58.31% -457.58% 0.11x 1.11x $-9.10 Million
2020 -106.51% -556.44% 0.15x 1.24x $-10.92 Million
2021 -33.99% -121.24% 0.18x 1.52x $-3.45 Million
2022 -111.14% -1263.03% 0.06x 1.43x $-8.80 Million
2023 0.00% -1968.54% 0.05x 0.00x $-9.21 Million

Industry Comparison

This section compares Beroni Group Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Beroni Group Limited (BNIGF) $5.56 Million -9.46% 0.52x $59.06K
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million